These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24704334)

  • 21. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.
    Beernink PT; Shaughnessy J; Pajon R; Braga EM; Ram S; Granoff DM
    PLoS Pathog; 2012; 8(5):e1002688. PubMed ID: 22589720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.
    Costa I; Pajon R; Granoff DM
    mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.
    Norheim G; Tunheim G; Næss LM; Kristiansen PA; Caugant DA; Rosenqvist E
    Scand J Immunol; 2012 Aug; 76(2):99-107. PubMed ID: 22537024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation and Immunogenicity of
    Manoharan S; Farman TA; Piliou S; Mastroeni P
    Front Immunol; 2024; 15():1473064. PubMed ID: 39380985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
    Giuntini S; Pajon R; Ram S; Granoff DM
    Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.
    Brunelli B; Del Tordello E; Palumbo E; Biolchi A; Bambini S; Comanducci M; Muzzi A; Pizza M; Rappuoli R; Donnelly JJ; Giuliani MM; Serruto D
    Vaccine; 2011 Jan; 29(5):1072-81. PubMed ID: 21130753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009.
    Ispasanie E; Pluschke G; Hodgson A; Sie A; MacLennan C; Koeberling O
    F1000Res; 2014; 3():264. PubMed ID: 25901274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
    Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
    Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.
    Granoff DM; Costa I; Konar M; Giuntini S; Van Rompay KK; Beernink PT
    J Infect Dis; 2015 Sep; 212(5):784-92. PubMed ID: 25676468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.
    Pinto VB; Burden R; Wagner A; Moran EE; Lee CH
    PLoS One; 2013; 8(11):e79304. PubMed ID: 24244473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
    McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
    mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.
    Rossi R; Konar M; Beernink PT
    Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.
    Beernink PT; Granoff DM
    Infect Immun; 2008 Jun; 76(6):2568-75. PubMed ID: 18362128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.